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Background and Aims: Type 2 diabetes is a progressive 
disease with associated insulin resistance and diminished 
insulin production. Treatment typically requires multiple 
agents, including insulin. PROactive was a study designed 
to evaluate the effects of pioglitazone on cardiovascular 
outcomes in 5,238 high-risk patients with type 2 diabetes. 
We examined insulin requirements and glycaemic control in 
the one-third of patients (n=864 in the pioglitazone group; 
n=896 in the placebo group) who were treated with insulin 
at baseline in PROactive. 
Materials and Methods: PROactive was a randomised, 
double-blind, placebo-controlled outcome study in patients 
with type 2 diabetes and macrovascular disease randomised 
to pioglitazone or matching placebo, in addition to their 
existing glucose-lowering and cardiovascular medication. 
Doses of pioglitazone were force-titrated to a dose of 
45 mg, if tolerated. Mean follow-up was 34.5 months. 
Within the cohort of patients receiving insulin at baseline, 
baseline mean daily insulin doses and HbA1c values were 
similar between treatment groups (pioglitazone: 47 U/d and 
8.4%; placebo: 47 U/d and 8.5%). In both groups at 
baseline, insulin was combined with oral monotherapy with 
metformin in 53% and sulfonylurea in 24% of patients and 
with dual therapy with metformin+sulfonylurea in 12%. 
Results: There was a rapid and sustained decrease in 
insulin dose with pioglitazone, whereas there was a 
progressive increase with placebo. By study end, the mean 
insulin dose was lower with pioglitazone (42 U/d) than with 
placebo (55 U/d; P<0.0001); nevertheless, a greater 
decrease in HbA1c was observed with pioglitazone 
(j0.93%) compared with placebo (j0.45%; P<0.0001). 
At final visit, insulin had been discontinued in 9% of 
patients in the pioglitazone group versus 2% in the placebo 
group (P<0.0001). The distribution of patients on oral/ 
insulin combined therapy remained similar in both groups: 
metformin alone in 47% versus 52%, sulfonylurea alone in 
16% versus 16%, and metformin+sulfonylurea in 10% 
versus 11%, in the pioglitazone group versus the placebo 
group, respectively (P=NS). There were differences in 
oedema (pioglitazone: 31%; placebo: 18%; P<0.0001) and 
hypoglycaemia (pioglitazone: 41%; placebo: 29%; 
P<0.0001), but there were no other differences in the safety 
profiles between the pioglitazone and placebo groups (with 
or without other treatments). 
Conclusion: Pioglitazone reduced the number of patients 
on insulin and the mean daily insulin dose while providing 
better glycaemic control than placebo. 
 
 
